Wechselwirkungen · Shingrix
Shingrix powder and suspension for suspension for injection Herpes zoster vaccine (recombinant, adjuvanted) · Abschnitt 4.5 · PDF-Seite 4
HOS-137953 · Präparat HOS-098121
In adults aged 50 years and above, systemic adverse reactions that are very commonly reported (see Table 1; such as myalgia 32.9%, fatigue 32.2%, and headache 26.3%), and arthralgia, uncommonly reported, following administration of Shingrix alone were reported with increased frequency when Shingrix was co-administered with a COVID-19 mRNA vaccine (myalgia 64%, fatigue 51.7%, headache 39%, arthralgia 30.3%).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-10-20T02:00:00Z · SHA-256 85082087d1e78d824692b73311f74bd22f2c91f3bb63e85a50437dd6319c83bc · Passage 297464561c9290b15c4834996f57fa3488b23e9abfa9000522e77add981b336a · Zeichen 711–1121 im Abschnitt